Pancreatic Carcinoma
75
16
25
21
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.0%
6 terminated out of 75 trials
77.8%
-8.8% vs benchmark
3%
2 trials in Phase 3/4
43%
9 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 21 completed trials
Clinical Trials (75)
Pilot Study of Pancreatic Cancer Screening
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Pancreatic Cancer Detection Consortium
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Use Of Indocyanine Green In Pancreas Surgery
The Vanguard Study: Testing a New Way to Screen for Cancer
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
A Study of MGC028 in Participants With Advanced Solid Tumors
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics